US4412990A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Composition having enhanced opsonic activity
Assignee: Bayer Corp
•
Filing: 1982-07-02
•
Granted: 1983-11-01
•
Expires: 2002-07-02
Abstract
Abstract There is disclosed a pharmaceutical composition for therapeutic use comprising an immune globulin and fibronectin in amounts sufficient to produce an opsonic activity in the composition that is greater than the additive opsonic activity of the individual agents or in amounts sufficient to produce a phagocytosis of infectious agents greater than the additive effect from fibronectin and immune globulin alone.
Inventors
- 👤 John L. Lundblad
- 👤 Miriam D. Budinger
- 👤 Richard S. Schwartz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 21:29
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/395; A61K39/40; A61P; A61P37/00; A61P37/02; A61P37/04
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
35 words
A pharmaceutical composition comprising purified immune globulin and fibronectin in amounts sufficient to produce an opsonic activity in the composition that is greater than the additive opsonic activity of the immune globulin and fibronectin alone.
Claim 2
Dependent Claim
35 words
A pharmaceutical composition comprising purified immune globulin and fibronectin in amounts sufficient to produce an opsonic activity in the composition that is greater than the additive opsonic activity of the immune globulin and fibronectin alone.
Claim 3
Dependent Claim
11 words
The composition of claim 1 which is a sterile aqueous solution.
Claim 4
Dependent Claim
19 words
The composition of claim 2 wherein the concentration of immune globulin and fibronectin is about 1-30%, weight to volume.
Claim 5
Dependent Claim
28 words
The composition of claim 2 wherein the immune globulin is intravenous immune globulin and the concentration of the immune globulin and fibronectin is about 5-15%, weight to volume.
Claim 6
Dependent Claim
28 words
The composition of claim 2 wherein the immune globulin is intramuscular immune globulin and the concentration of the immune globulin and fibronectin is about 10-20%, weight to volume.
Claim 7
Dependent Claim
19 words
The composition of claim 1 which contains 0.01-1000 parts of immune globulin per part of fibronectin, weight to weight.
Claim 8
Dependent Claim
19 words
The composition of claim 6 which contains 0.1-500 parts of immune globulin per part of fibronectin, weight to weight.
Claim 9
Dependent Claim
18 words
The composition of claim 7 which contains 1-100 parts of immune globulin part of fibronectin, weight to weight.
Claim 10
Dependent Claim
13 words
The composition of claim 1 wherein the immune globulin is immune serum globulin.
Claim 11
Dependent Claim
15 words
The composition of claim 9 wherein the immune serum globulin is suitable for intravenous administration.
Claim 12
Dependent Claim
52 words
A pharmaceutical composition suitable for intravenous administration for treatment of impaired reticuloendothelial system function and reduced ability for opsonization of infectious agents, which comprises an intravenously injectable purified immune globulin and fibronectin in the ratio of about 0.01-1000 parts of immune globulin per part of fibronectin, on a weight to weight basis.
Claim 13
Dependent Claim
52 words
A pharmaceutical composition suitable for intravenous administration for treatment of impaired reticuloendothelial system function and reduced ability for opsonization of infectious agents, which comprises an intravenously injectable purified immune globulin and fibronectin in the ratio of about 0.01-1000 parts of immune globulin per part of fibronectin, on a weight to weight basis.
Claim 14
Dependent Claim
23 words
The composition of claim 11 which contains about 0.1-500 parts of immune globulin per part of fibronectin on a weight to weight basis.
Claim 15
Dependent Claim
23 words
The composition of claim 11 which contains about 1-100 parts of immune globulin per part of fibronectin, on a weight to weight basis.
Claim 16
Dependent Claim
27 words
The composition of claim 11 wherein the combined concentration of immune globulin and fibronectin is about 1-30% in an aqueous medium, on a weight to volume basis.
Claim 17
Dependent Claim
30 words
A method of treating a patient having impaired reticuloendothelial system function and reduced ability for opsonization of infectious agents which comprises administering to the patient the composition of claim 11.
Claim 18
Dependent Claim
30 words
A pharmaceutical composition comprising purified immune globulin and fibronectin in amounts sufficient to produce a phagocytosis of infectious agents greater than the additive effect from fibronectin and immune globulin alone.
Claim 19
Dependent Claim
30 words
A pharmaceutical composition comprising purified immune globulin and fibronectin in amounts sufficient to produce a phagocytosis of infectious agents greater than the additive effect from fibronectin and immune globulin alone.
Claim 20
Dependent Claim
23 words
The composition of claim 16 which contains about 0.01-1000 parts of immune globulin per part of fibronectin, on a weight to weight basis.
Claim 21
Dependent Claim
27 words
The composition of claim 16 wherein the combined concentration of immune globulin and fibronectin is about 1-30% in an aqueous medium, on a weight to volume basis.
Claim 22
Dependent Claim
15 words
In a composition comprising an immune globulin, the improvement comprising fibronectin in a synergistic amount.
Claim 23
Dependent Claim
15 words
In a composition comprising an immune globulin, the improvement comprising fibronectin in a synergistic amount.
Claim 24
Dependent Claim
16 words
The composition of claim 19 which contains 0.1-500 parts of immune globulin per part of fibronectin.
Claim 25
Dependent Claim
10 words
The composition of claim 19 which further includes a carbohydrate.
Claim 26
Dependent Claim
15 words
The composition of claim 21 wherein the amount of carbohydrate is about 1-20% by weight.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-10-31 | 1987-05-02 | 1987-11-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-10-31 | 1991-05-02 | 1991-11-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-10-31 | 1995-05-02 | 1995-11-01 | $7700.00 | Window Closed / Lapsed |